BIVI - Multiplikator Forward P/S BioVie

Tandha merek BioVie Inc (BIVI)

BioVie Inc. (BIVI) management is focusing on dementia and liver pathology therapies, foregoing dividend payments to fund clinical trial development. The GURU.Markets terminal displays a forward P/S ratio chart, where the current reading is , confirming market confidence. The production of hepatoprotectors has been outsourced to external CDMO partners to optimize processes, while innovative drugs target inflammation and brain insulin resistance.

BIVI BioVie Pharma: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 04.07.2022 - 13.11.2026

Rincian analitis perusahaan BioVie Inc.

- rega saiki lan proyeksi nilai saham:
Rega saham BioVie|BIVI - Bagan rega target
- statistik kapitalisasi pasar:
Kapitalisasi pasar BIVI|BIVI - Rega Tumbas Perusahaan
- statistik nilai buku emiten:
Aset Bersih saben Siji Saham BioVie|BIVI - Ekuitas Perusahaan|Rasio Kapitalisasi marang Aset Bersih biovieinc.com|BIVI - Aset Agregat Perusahaan
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal BioVie Inc.|BIVI - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang modal BioVie|BIVI - Utang kumulatif perusahaan|Utang marang nilai buku BIVI|BIVI - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan BioVie|Likuiditas cepet biovieinc.com
- data bathi bisnis lan rasio investasi:
BIVI - Bathi perusahaan|Proyeksi bathi mangsa ngarep BioVie Inc.|BIVI - Koefisien rega marang bathi|Prakiraan rega marang bathi BioVie|BIVI - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA BIVI|BIVI - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) BioVie|BIVI - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan biovieinc.com|BIVI - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep BioVie Inc.
- rincian pendapatan lan dodolan:
BIVI - Pendapatan reged perusahaan|Prakiraan pendapatan perusahaan BioVie|BIVI - Rasio rega marang dodolan|Multiplikator Forward P/S BIVI
Analisis wiwitan perusahaan:BioVie Pharma (BIVI)
Sampel barang biovieinc.com

Forward P/S assesses market capitalization relative to expected annual sales, allowing an investor to determine the extent of overpayment for future cash flows via the projected P/S parameter. For BioVie Inc. (BIVI), this metric reflects the speculative value of potential drug approvals rather than a market cycle, where the coefficient's dynamics depend directly on the success of clinical trials and the availability of venture capital.

Pesaing wigati

Multiplikator Forward P/S ARWR (Arrowhead Pharmaceuticals, Inc.)|Mirum Pharmaceuticals, Inc. - Rasio rega marang prakiraan pendapatan|Dynavax Pharma - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Tekmira Pharmaceuticals ABUS|Inventiva S.A. (IVA) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep gyretx.com (GYRE)|Multiplikator forward rega marang pendapatan ASMB|Rasio rega marang prakiraan pendapatan GALT|Multiplikator Forward P/S GNFT|Rasio kapitalisasi marang dodolan sing dikarepake durect.com|Multiplikator Forward P/S ALGS (Aligos Therapeutics, Inc.)|Galmed Pharmaceuticals Ltd (GLMD) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|NDRA: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan HEPA (Hepion Pharmaceuticals)